Portland, OR -- (SBWIRE) -- 09/07/2017 -- Filgrastim is a granulocyte colony-stimulating factor in humans and a hematopoietic agent utilized for prevention of infection and neutropenic (low count of WBCs) fevers triggered by chemotherapy, HIV/AIDS, radiation poisoning, or others. Filgrastim can be administered by subcutaneous injection or infused into vein by IV.
Increase in prevalence of various diseases and surge in geriatric population drives the market growth. Moreover, increase in pressure to decrease healthcare expenditure and surge in demand for filgrastim due to its cost effectiveness is anticipated to boost the growth of this market. However, dearth of trained healthcare professionals and accuracy of devices impede the market growth.
The Global Filgrastim Market is segmented on the basis of type of manufacturing, application, and geography. Based on type of manufacturing, it is bifurcated into in-house manufacturing and contract manufacturing organizations. Based on application the market is divided into oncology, chronic and autoimmune diseases, blood disorders, growth hormone deficiency, infectious diseases, and others. By geography, it is analyzed across North America, Europe, Asia Pacific, and LAMEA.
Comprehensive competitive analysis and profiles of major market players such as Cadila Pharmaceuticals Ltd, Abbott Laboratories Inc., Dr. Reddy's Laboratories Inc, Intas Biopharmaceuticals Ltd, Amgen Inc., Emcure Pharmaceuticals Ltd, Reliance Life Sciences Pvt. Ltd, Novartis AG, and Sandoz Inc, and Biocon Ltd. are provided in this report.
Get PDF Brochure of this report: https://www.alliedmarketresearch.com/request-toc-and-sample/3643
Filgrastim Market Key Segments:
By Type of Manufacturing
- In-House Manufacturing
- Contract Manufacturing Organizations
- Chronic and Autoimmune Diseases
- Blood Disorders
- Growth Hormone Deficiency
- Infectious Diseases
- Other Applications
Early buyers will receive 20% customization on this report